Business Wire

NJ-SEMPERIS

4.5.2021 15:02:07 CEST | Business Wire | Press release

Share
Semperis Enhances the Industry’s Most Comprehensive Active Directory Protection Platform with Continuous Security Validation

Semperis , the pioneer of identity-driven cyber resilience for enterprises, today announced the general availability of Directory Services Protector (DSP) v3.5, which includes DSP Intelligence, a new module that provides automated security assessments of Microsoft Active Directory (AD). DSP Intelligence proactively uncovers dangerous vulnerabilities that arise from external threat actors, systemic weaknesses in default identity and access settings, and even internal configuration drift that leads to security regression.

The company also announced enhancements to Active Directory Forest Recovery (ADFR), the only disaster recovery product for AD purpose-built to combat cyberattacks. New ADFR capabilities include unique backup set encryption keys, advanced forensics search, and extended support for SAML and MFA authentication.

The continuous security assessment capabilities now available in DSP Intelligence address the skyrocketing proliferation of cyberattacks—including the infamous SolarWinds supply-chain attack and the Hafnium attack on Microsoft Exchange—that target identity systems, especially AD. As the gatekeeper to critical applications and data in 90% of organizations worldwide, AD is a common access vector for attackers and extremely complex to secure given its constant flux, sheer number of settings, and the increasingly sophisticated threat landscape. Findings from companies using Semperis’ free Purple Knight security assessment tool revealed that even large organizations with significant investments in security resources are failing to close critical gaps in AD, scoring an average of 61%, with Kerberos authentication being the top risk area.

“Active Directory is a critical piece of most enterprises’ IT infrastructure but is notoriously difficult to keep secure,” said Darren Mar-Elia, Vice President of Products at Semperis. “Not only are its settings complex, but both AD itself and attack paths are constantly evolving. Organizations must be able to ensure their directory services are secure on a continual basis—not just at a point in time—while actively testing against the latest indicators for new attacks and threats. DSP Intelligence is designed to provide a larger range of security indicators and advance pre-attack tests to harden AD against new adversary TTPs and spot your weaknesses before attackers do. The threat hunting capabilities have also proven to be extremely helpful for organizations in post-breach scenarios to understand how attackers broke in and how to close backdoors for good.”

A growing number of breaches involve the exploitation of suboptimal AD configurations to allow attackers to gain a foothold within target networks, access sensitive resources, and deploy malware. To get ahead of attackers, DSP Intelligence continuously queries an organization’s AD environment and performs a comprehensive set of tests against the most common and effective attack vectors that correlate to known security frameworks such as the MITRE ATT&CK.

With the addition of DSP Intelligence, Semperis further establishes DSP as the industry’s most comprehensive AD threat detection and response platform. Semperis also updated the complementary modules, DSP Essential and DSP Advanced, which address foundational directory security and operational use cases:

  • DSP Essential – AD change tracking and rollback
  • DSP Advanced – Autonomous threat protection and response
  • DSP Intelligence – Security validation and breach prevention

To see DSP Intelligence in action, watch the five-minute video overview: https://pages.semperis.com/dsp-intelligence-video-intro/

For more information about DSP and ADFR, visit the product pages below:

About Semperis

For security teams charged with defending hybrid and multi-cloud environments, Semperis ensures integrity and availability of critical enterprise directory services at every step in the cyber kill chain and cuts recovery time by 90%. Purpose-built for securing Active Directory, Semperis’ patented technology protects over 40 million identities from cyberattacks, data breaches, and operational errors. The world’s leading organizations trust Semperis to spot directory vulnerabilities, intercept cyberattacks in progress, and quickly recover from ransomware and other data integrity emergencies. Semperis is headquartered in New Jersey and operates internationally, with its research and development team distributed between San Francisco and Tel Aviv.

Semperis hosts the award-winning Hybrid Identity Protection conference (www.hipconf.com ). The company has received the highest level of industry accolades and was recently ranked the fourth fastest-growing company in the tri-state area and 35th overall in Deloitte’s 2020 Technology Fast 500™ . Semperis is accredited by Microsoft and recognized by Gartner.

Twitter https://twitter.com/SemperisTech
LinkedIn https://www.linkedin.com/company/semperis
Facebook https://www.facebook.com/SemperisTech
YouTube https://www.youtube.com/channel/UCycrWXhxOTaUQ0sidlyN9SA

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye